总之,随着时间的推移,驱动基因的改变可能在MLL -AML 的进展中起重要作用。 结果如下: 结果一:白血病在阶段性移植中的转化和发病,结果表明MLL/AF9转导小鼠白血病细胞阶段性移植导致骨髓再生时间缩短,表现出与复发的人MLL-AML相似的侵袭性表型。 图1:小鼠M...
分析成人AML伴MLL重排患者的临床特征及预后影响因素 混合谱系白血病(malignantlymphoma,MLL)由国外学者于上世纪90年代初首次报道, 其位于人体11q23区域,已被证实是血液系统恶性肿瘤常见遗传学改变,如急性白血病、 骨髓增生异常综合征(myelodysplasticsyndormes,MDS)等[1]。有遗传学研究证实,MLL ...
BACKGROUND: Mixed lineage leukemia (MLL) gene rearrangements in AML patients always had very poor prognosis. In this study, Reported that the incidence of rearrangements in patients with acute myeloid leukemia MLL gene analysis of clinical significance and prognostic features. MATERIAL AND METHODS : T...
The onset of leukemia was progressively promoted with advanced transplants, during which increasing numbers of somatic mutations were acquired (P < 0.005). Among these, mutations in Ptpn11 (p.G60R) and Braf (p.V637E) corresponded to those identified in human MLL-AML, while recurrent mutations...
作者发现FOXM1上调可激活WNT/β-catenin信号通路,与β-catenin结合,抑制β-catenin的降解,从而促进MLL-r AML(在婴儿中发生率占70%,在AML中占10%)LSC的自我更新。且MLL-AF9 AML病人的LSC对FOXM1抑制剂敏感,而正常的造血干细胞HSC对FOXM1抑制剂...
结论:应用多重巢式PCR方法筛选AML患者中的MLL基因方便、快捷、经济、准确的。对于MLL基因重排AML患者中(Allo-HSCT)能够明显延长OS,能更好的获得较好的预后及长期生存。发病时血小板计数为OS及DFS的独立预后因素。CR为OS的独立预后因素,髓外受累是DFS的独立预后因素。MRD阴性患者预后较好。发病时血小板减少的MLL基因重排...
1.由KMT2A-MLLT3融合基因引起的急性髓系白血病(AML)伴t(9;11)(p21.3;q23.3)通常具有单核细胞的特征。 2.t(9;11)(p21.3;q23.3)可见于任何年龄,但在儿童中更为常见;可见于9-12%的儿童AML和2%成年急性髓系白血病患者中。 3.患者可出现弥散血管内凝血(DIC),可出现髓外的髓系肉瘤和/或组织浸润(齿龈、皮...
Figure. Targeting Menin-MLL Interactions In preclinical research, KO-539 prolonged survival compared with quizartinib, a FLT3 inhibitor, in 2 patient-derived xenograft models of NPM1/DNMT3/FLT3-mutant AML. In a confirmatory study, animals that were NPM1- and FLT3-mutant/DNMT3A wild-type and...
产品活性:Revumenib (SNDX-5613) 是一种有效的特异性 Menin-MLL 抑制剂,结合 Ki 为 0.149 nM,细胞实验中,抑制 Menin-MLL 的 IC50 为 10-20 nM。Revumenib 可用于 MLL 基因重排的急性白血病研究,包括急性淋巴细胞白血病 (ALL) 和急性髓细胞白血病 (AML)。
It is published monthly and covers all aspects of the research and treatment of leukemia and allied diseases. Studies of normal hemopoiesis are covered because of their comparative relevance.doi:10.1038/sj.leu.2403768Bogni, APui, C-HRelling, M VLeukemiaLeukemia...